Evaluating Polygenic Risk Scores for Breast Cancer in Women of African Ancestry.
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
04 09 2021
04 09 2021
Historique:
received:
07
08
2020
revised:
03
02
2021
accepted:
22
03
2021
pubmed:
27
3
2021
medline:
25
2
2022
entrez:
26
3
2021
Statut:
ppublish
Résumé
Polygenic risk scores (PRSs) have been demonstrated to identify women of European, Asian, and Latino ancestry at elevated risk of developing breast cancer (BC). We evaluated the performance of existing PRSs trained in European ancestry populations among women of African ancestry. We assembled genotype data for women of African ancestry, including 9241 case subjects and 10 193 control subjects. We evaluated associations of 179- and 313-variant PRSs with overall and subtype-specific BC risk. PRS discriminatory accuracy was assessed using area under the receiver operating characteristic curve. We also evaluated a recalibrated PRS, replacing the index variant with variants in each region that better captured risk in women of African ancestry and estimated lifetime absolute risk of BC in African Americans by PRS category. For overall BC, the odds ratio per SD of the 313-variant PRS (PRS313) was 1.27 (95% confidence interval [CI] = 1.23 to 1.31), with an area under the receiver operating characteristic curve of 0.571 (95% CI = 0.562 to 0.579). Compared with women with average risk (40th-60th PRS percentile), women in the top decile of PRS313 had a 1.54-fold increased risk (95% CI = 1.38-fold to 1.72-fold). By age 85 years, the absolute risk of overall BC was 19.6% for African American women in the top 1% of PRS313 and 6.7% for those in the lowest 1%. The recalibrated PRS did not improve BC risk prediction. The PRSs stratify BC risk in women of African ancestry, with attenuated performance compared with that reported in European, Asian, and Latina populations. Future work is needed to improve BC risk stratification for women of African ancestry.
Sections du résumé
BACKGROUND
Polygenic risk scores (PRSs) have been demonstrated to identify women of European, Asian, and Latino ancestry at elevated risk of developing breast cancer (BC). We evaluated the performance of existing PRSs trained in European ancestry populations among women of African ancestry.
METHODS
We assembled genotype data for women of African ancestry, including 9241 case subjects and 10 193 control subjects. We evaluated associations of 179- and 313-variant PRSs with overall and subtype-specific BC risk. PRS discriminatory accuracy was assessed using area under the receiver operating characteristic curve. We also evaluated a recalibrated PRS, replacing the index variant with variants in each region that better captured risk in women of African ancestry and estimated lifetime absolute risk of BC in African Americans by PRS category.
RESULTS
For overall BC, the odds ratio per SD of the 313-variant PRS (PRS313) was 1.27 (95% confidence interval [CI] = 1.23 to 1.31), with an area under the receiver operating characteristic curve of 0.571 (95% CI = 0.562 to 0.579). Compared with women with average risk (40th-60th PRS percentile), women in the top decile of PRS313 had a 1.54-fold increased risk (95% CI = 1.38-fold to 1.72-fold). By age 85 years, the absolute risk of overall BC was 19.6% for African American women in the top 1% of PRS313 and 6.7% for those in the lowest 1%. The recalibrated PRS did not improve BC risk prediction.
CONCLUSION
The PRSs stratify BC risk in women of African ancestry, with attenuated performance compared with that reported in European, Asian, and Latina populations. Future work is needed to improve BC risk stratification for women of African ancestry.
Identifiants
pubmed: 33769540
pii: 6189099
doi: 10.1093/jnci/djab050
pmc: PMC8418423
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1168-1176Subventions
Organisme : NIGMS NIH HHS
ID : T32 GM008692
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA058223
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA228198
Pays : United States
Organisme : CIHR
Pays : Canada
Organisme : NICHD NIH HHS
ID : P2C HD050924
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Am J Hum Genet. 2019 Jan 3;104(1):21-34
pubmed: 30554720
Int J Epidemiol. 2022 Jan 6;50(6):1897-1911
pubmed: 34999890
Nat Genet. 2019 Apr;51(4):584-591
pubmed: 30926966
Hum Genet. 2013 Jan;132(1):39-48
pubmed: 22923054
Breast Cancer Res. 2022 Jan 4;24(1):2
pubmed: 34983606
Breast Cancer Res. 2016 Dec 8;18(1):124
pubmed: 27931260
J Med Genet. 2019 Sep;56(9):581-589
pubmed: 31186341
PLoS Genet. 2016 Sep 02;12(9):e1006288
pubmed: 27589268
Nat Commun. 2020 Jul 31;11(1):3833
pubmed: 32737321
Cancer Causes Control. 2014 Mar;25(3):309-19
pubmed: 24343304
JAMA. 2016 Jan 5;315(1):68-76
pubmed: 26746459
Nat Genet. 2017 Dec;49(12):1767-1778
pubmed: 29058716
Genet Med. 2019 Aug;21(8):1708-1718
pubmed: 30643217
Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):126-135
pubmed: 27697780
Ann Intern Med. 2009 Nov 17;151(10):716-26, W-236
pubmed: 19920272
PLoS One. 2020 Feb 5;15(2):e0228198
pubmed: 32023287
Obstet Gynecol. 2011 Aug;118(2 Pt 1):372-382
pubmed: 21775869
Int J Cancer. 2020 Jun 1;146(11):2987-2998
pubmed: 31469419
J Natl Cancer Inst. 2015 Apr 08;107(5):
pubmed: 25855707
PLoS Med. 2018 Sep 4;15(9):e1002644
pubmed: 30180161
J Natl Cancer Inst. 2020 Mar 1;112(3):278-285
pubmed: 31165158
Cancer Epidemiol Biomarkers Prev. 2018 Apr;27(4):405-417
pubmed: 28637795
Am J Hum Genet. 2017 Apr 6;100(4):635-649
pubmed: 28366442
Nat Commun. 2020 Mar 5;11(1):1217
pubmed: 32139696
J Natl Cancer Inst. 2017 Aug 1;109(8):
pubmed: 29117387
J Glob Health. 2018 Jun;8(1):010419
pubmed: 29740502
Hum Mol Genet. 2016 Nov 1;25(21):4835-4846
pubmed: 28171663
Genet Epidemiol. 2017 Dec;41(8):811-823
pubmed: 29110330
Breast Cancer Res Treat. 2019 Jul;176(1):141-148
pubmed: 30941651
PLoS One. 2015 Mar 04;10(3):e0118432
pubmed: 25738806
J Clin Oncol. 2017 Mar;35(7):743-750
pubmed: 28029312
Nature. 2017 Nov 2;551(7678):92-94
pubmed: 29059683
JAMA. 2015 Oct 20;314(15):1599-614
pubmed: 26501536
Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):1016-1026
pubmed: 28377418
J Natl Cancer Inst. 2020 Jun 1;112(6):590-598
pubmed: 31553449